The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Florida Research Foundation, Incorporated

Cornell Research Foundation Inc.

Centers for Disease Control and Prevention

Purdue Research Foundation

Intervet International B.v.

Jacqueline M Katz

Alexander I Klimov

Edward Joseph Dubovi

Mark William Mellencamp

Nancy J Cox

Melissa Anne Lum

Daniel Ghislena Emiel Goovaerts

Nallakannu P Lakshmanan

Ruben Omar Donis

Paul J Gibbs

William L Castleman

Patti Cynthia Crawford

Suresh Kumar Mittal

A Michael Frace

Suryaprakash Sambhara

Mary Hoelscher

Dinesh S Bangari

The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

Materials and methods for respiratory disease control in canines

The present disclosure provides compositions and methods for eliciting an immune response against avian or pandemic influenza. The compositions include adenovirus vectors comprising avian influenza antigens, recombinant adenovirus and immunogenic compositions comprising such recombinant vectors and adenovirus. Methods for eliciting an immune response against avian or pandemic influenza involving administering such adenovirus vectors or recombinant adenovirus are also provided.

Vaccine against pandemic strains of influenza viruses

The present invention provides a method of increasing the recombinant expression and solubility of influenza A virus M2 polypeptide comprising nucleic acids encoding variants of the M2 protein of influenza A virus in which transmembrane and other hydrophobic domains have been deleted. The present invention also provides purified polypeptides encoded by the nucleic acids, which polypeptides are immunogenic and are less hydrophobic than full-length M2. Also provided are vaccines comprising variants of M2 expressed in prokaryotic hosts. Further provided are methods of preventing influenza A infection using vaccines comprised of variants of M2. Also provided are antibodies raised against the variants of M2, and use of such antibodies in diagnosis and treatment of influenza A infections.

Preparation and use of recombinant influenza A virus M2 construct vaccines

Growing community of inventors

Atlanta, GA, United States of America

Jacqueline M Katz